A first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC.
Katsuyuki Kiura
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Takashi Seto
Honoraria - Chugai Pharma
Nobuyuki Yamamoto
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Makoto Nishio
Honoraria - Chugai Pharma
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Tomohide Tamura
Honoraria - Chugai Pharma